Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Shanghai Zhongshan Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07314372CT.gov FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT03607643CT.gov A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | — | Unknown | — | — | — |
NCT01324076CT.gov Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | — | Unknown | — | — | — |
NCT01164202CT.gov Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer | — | Completed | — | — | — |
NCT01009801CT.gov Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer | — | Terminated | — | — | — |
NCT01042041CT.gov Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer | — | Completed | — | — | — |
NCT01011010CT.gov Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00949182CT.gov Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT00524316CT.gov Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | — | Terminated | — | — | — |
NCT00471484CT.gov Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery | — | Unknown | — | — | — |
Show 6 more trialsShow fewer
NCT00276705CT.gov Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer | — | Unknown | — | — | — |
NCT00093444CT.gov Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors | — | Completed | — | — | — |
NCT00047229CT.gov Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) | — | Completed | — | — | — |
NCT00012324CT.gov Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer | — | Completed | — | — | — |
NCT00004248CT.gov Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT00003296CT.gov Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Liver Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | Shanghai Zhongshan Hospital | Approved | BB · 68 |
| Dexmedetomidine | Uppsala University Hospital | P4 | BBB |
| Oxaliplatin | Sun Yat-sen University | P3 | BB |
| Tranexamic Acid | Konkuk University Medical Center | P4 | BB |
| Hepatitis B Virus Vaccine | Eunice Dube | P4 | BB |
| Sufentanyl | The Second Affiliated Hospital of Chongqing Medical University | P4 | BB |
| Sorafenib | First Affiliated Hospital Xi'an Jiaotong University | P3 | BB |
| Gardasil 9 Vaccine | Eunice Dube | P4 | BB |
| Idarubicin | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
+42 more in the Liver Cancer cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adriamycin in Liver Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-liver-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →